Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAI-OCTA Study
NCT03022292Phase 4Completed
- Sponsor
- University of California, Los Angeles
- Start
- Mar 2017
- Primary completion
- Jun 2020
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by University of California, Los Angeles. Started Mar 2017; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03022292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03022292.